Amgen keeps Kineret
Executive Summary
Amgen will keep IL-1 inhibitor Kineret (anakinra) for treatment of rheumatoid arthritis under a proposed consent agreement between Amgen and Federal Trade Commission that would allow the company's proposed acquisition of Immunex to proceed. FTC's July 12 announcement of the agreement notes that Kineret has had sales in excess of $2.4 mil. since its launch in November. The agreement would require the company to divest one of Immunex' marketed products, the neutrophil regeneration factor Leukine (sargramostim) (1"The Pink Sheet" Dec. 24, 2001, p. 16)...
You may also be interested in...
Kineret Gets Rheumatologist Promotions From 35-Rep NPS Force
NPS will promote Amgen's rheumatoid arthritis agent Kineret to rheumatologists with a 35 member specialty sales force
Leukine Is Divestment Candidate In Amgen/Immunex Deal
Immunex' Leukine is available for licensing as part of Amgen's acquisition of the biotech company
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.